Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study

[1]  Y. Okabe,et al.  A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study , 2021, International Journal of Clinical Oncology.

[2]  M. Fredrikson,et al.  Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer , 2020, Frontiers in Oncology.

[3]  Wu-Hu Zhang,et al.  Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer , 2020, World journal of gastroenterology.

[4]  J. Furuse,et al.  Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines , 2020, Journal of Gastroenterology.

[5]  C. Lu,et al.  Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second‐line palliative chemotherapy , 2019, Journal of gastroenterology and hepatology.

[6]  S. Hayami,et al.  Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. , 2019, Surgery.

[7]  D. V. Von Hoff,et al.  NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. , 2019, European journal of cancer.

[8]  Joon-Oh Park,et al.  TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). , 2019, European journal of cancer.

[9]  Zhiqiang Sun,et al.  Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real‐world study , 2018, Cancer medicine.

[10]  Zhaoshen Li,et al.  Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma , 2017, Scientific Reports.

[11]  M. Malafa,et al.  Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. , 2016, Surgery.

[12]  Y. Ku,et al.  Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios , 2016, Surgery Today.

[13]  A. Carrato,et al.  A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs , 2015, Journal of Gastrointestinal Cancer.

[14]  Ben Tran,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[15]  B. Dörken,et al.  Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.

[16]  U. Mansmann,et al.  Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer , 2010, Tumor Biology.

[17]  F. Gay,et al.  Prognostic Factors and Prognostic Index for Chemonaïve and Gemcitabine-Refractory Patients with Advanced Pancreatic Cancer , 2008, Oncology.